Apatinib Combined With POF for Second-line Treatment of Gastric Adenocarcinoma
Status:
Unknown status
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
In previous studies,the investigators found that POF (A combination of oxaliplatin,
fluorouracil and Paclitaxel) regimen appears to be of good efficacy and is well tolerated in
patients with advanced gastric cancer. Apatinib is an orally antiangiogenic agent. It was
approved and launched in China in 2014 as a 3rd-line treatment for patients with advanced
gastric cancer. Therefore, investigators conducted the dose escalation phase I study to
explore the safety of combination of apatinib and POF as first-line treatment for advanced
gastric cancer. Now the investigators are going to start a phase 2 trial with apatinib 500mg
+ POF as second-line therapy to investigate the efficacy and safety in the patients with
advanced gastric cancer.